Diphtheria Vaccine Market, by Vaccine Type (DTaP vaccine, DT vaccine, Tdap vaccine, and Td vaccine), by Age Group (Pediatrics and Adults), by End User (Hospitals, Clinics, and Vaccination Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023

Code : CMI5480

Pages :190

Formats :

Excel and PDF

Industry : Pharmaceutical

Regional Analysis

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa

Global Diphtheria Vaccine Market- Regional Analysis

Among regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 34.8% market share and due to presence of large number key market player in this region. Key market players such as AJ Vaccines A/S., GlaxoSmithKline plc., Merck & Co., Inc, Sanofi, and others have their strong presence in this region.

The Europe region is expected to be second largest region over the forecast period. Due to increasing prevalence of dermatological disease in Europe. For instance, in March 2022, according to article published by National Library of Medicine, in 2021, 185,103,774 individuals in Europe affected by dermatological condition or disease.